Moderna and Merck's experimental cancer vaccine, when used in combination with Keytruda ... a treatment for non-small cell lung cancer. Melanoma is responsible for the large majority of skin ...

Health-related quality of life among patients with stage 3 melanoma was not significantly affected after receiving ...

Moderna announced Thursday that an experimental cancer vaccine it is developing with Merck – when combined with the latter’s Keytruda immunotherapy ... serious form of skin cancer" by ...

US-based Merck said the pivotal phase 3 trial investigating Keytruda monotherapy as a first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) had met one of ...

Merck & Co.’s drug Keytruda failed to help people with cancer in two clinical trials, both using the immunotherapy as an add-on to other types of treatment for early-stage lung and skin cancer ...

Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

This year, Merck's combination immunotherapy of vibostolimab and Keytruda faced two separate trial discontinuations when evaluated as treatments for lung and skin cancer. In recent months ...

A GROUNDBREAKING cancer vaccine could stop tumours growing in patients with advanced disease, researchers say. Designed to ...

Today we highlight research findings reported at ESMO 2024, the annual meeting of the European Society of Medical Oncology.

Recommended Reading Biomarker data help Merck case for wide use of Keytruda combo Merck ... as an add-on to other types of treatment for early-stage lung and skin cancer, the comapny said ...